OPKO Health, Inc. announced that it has received $250 million in funding from Healthcare Royalty Management, LLC
July 16, 2024
Share
OPKO Health, Inc. announced that it ahs entered into non-dilutive note purchase agreement with new investor Healthcare Royalty Management, LLC to issue a convertible note for the gross proceeds of $250,000,000 on July 17, 2024. The note issued under the Note Purchase Agreement bears interest at the 3-month Secured Overnight Financing Rate (SOFR) subject to a 4% per annum floor, plus 7.5% per annum. The note has a final maturity date of July 2044 with the first four years requiring interest only payments.
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.